Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment

Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment

JHVEPhoto/iStock Editorial by way of Getty Photographs Abeona Therapeutics (NASDAQ:ABEO) introduced that the FDA has accepted for assessment Abeona’s resubmission of its Biologics License Utility for prademagene zamikeracel, its investigational autologous cell-based gene remedy, as a possible new therapy for recessive dystrophic epidermolysis bullosa. The FDA has assigned a Prescription Drug Person Price Act goal … Read more

Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com

Axsome Therapeutics stock hits 52-week high at .61 By Investing.com

Axsome Therapeutics Inc . (NASDAQ:) inventory soared to a 52-week excessive, reaching a worth stage of $98.61, marking a big milestone for the corporate. This peak displays a strong 1-year change, with the inventory worth climbing a powerful 55.57%. Buyers have proven elevated confidence in Axsome’s development prospects, driving the inventory to outperform inside its … Read more